Is HXB2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of HXB2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate HXB2's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate HXB2's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for HXB2?
Key metric: As HXB2 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
The above table shows the Price to Book ratio for HXB2. This is calculated by dividing HXB2's market cap by their current
book value.
What is HXB2's PB Ratio?
PB Ratio
4.9x
Book
US$2.91m
Market Cap
US$14.33m
HXB2 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Book vs Industry: HXB2 is expensive based on its Price-To-Book Ratio (4.9x) compared to the European Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is HXB2's PB Ratio
compared to its
Fair PB Ratio?
This is the expected PB Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
HXB2 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio
4.9x
Fair PB Ratio
n/a
Price-To-Book vs Fair Ratio: Insufficient data to calculate HXB2's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst HXB2 forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
€0.17
€2.88
+1,584.7%
66.7%
€4.80
€0.96
n/a
2
Nov ’25
€0.22
€2.93
+1,207.2%
52.1%
€4.62
€0.92
n/a
3
Oct ’25
€0.19
€3.17
+1,584.5%
35.0%
€4.52
€1.81
n/a
3
Sep ’25
€0.27
€3.17
+1,072.9%
35.0%
€4.52
€1.81
n/a
3
Aug ’25
€0.28
€3.30
+1,079.6%
37.1%
€4.84
€1.84
n/a
3
Jul ’25
€0.30
€3.30
+1,000.9%
37.1%
€4.84
€1.84
n/a
3
Jun ’25
€0.30
€3.30
+1,015.8%
37.1%
€4.84
€1.84
n/a
3
May ’25
€0.35
€3.28
+847.6%
35.0%
€4.68
€1.87
n/a
3
Apr ’25
€0.44
€2.53
+471.5%
27.3%
€3.21
€1.84
n/a
2
Mar ’25
€0.33
€3.50
+961.5%
43.0%
€5.48
€1.83
n/a
3
Feb ’25
€0.36
€3.50
+884.0%
43.0%
€5.48
€1.83
n/a
3
Jan ’25
€0.43
€3.50
+710.9%
43.0%
€5.48
€1.83
n/a
3
Dec ’24
€0.39
€3.50
+789.1%
43.0%
€5.48
€1.83
n/a
3
Nov ’24
€0.42
€3.58
+759.5%
43.0%
€5.60
€1.87
€0.22
3
Oct ’24
€0.39
€3.58
+816.8%
43.0%
€5.60
€1.87
€0.19
3
Sep ’24
€0.57
€3.59
+524.7%
44.9%
€5.73
€1.83
€0.27
3
Aug ’24
€0.57
€3.66
+543.0%
44.9%
€5.85
€1.87
€0.28
3
Jul ’24
€0.60
€3.66
+505.8%
44.9%
€5.85
€1.87
€0.30
3
Jun ’24
€0.38
€3.66
+869.5%
44.9%
€5.85
€1.87
€0.30
3
May ’24
€0.44
€4.89
+1,022.0%
30.9%
€5.96
€2.75
€0.35
3
Apr ’24
€0.34
€5.20
+1,431.7%
31.6%
€6.48
€2.88
€0.44
3
Mar ’24
€0.48
€5.20
+977.9%
31.6%
€6.48
€2.88
€0.33
3
Feb ’24
€0.49
€5.20
+959.7%
31.6%
€6.48
€2.88
€0.36
3
Jan ’24
€0.28
€5.20
+1,765.6%
31.6%
€6.48
€2.88
€0.43
3
Dec ’23
€0.37
€5.20
+1,289.4%
31.6%
€6.48
€2.88
€0.39
3
Nov ’23
€0.58
€5.52
+849.7%
33.2%
€7.17
€2.97
€0.42
3
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.